CD8⁺ CD28^- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study

Affiliations

• ¹ Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
• ² Laborarztpraxis Rhein-Main MVZ GbR, Frankfurt am Main, Germany.
• ³ Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.
• ⁴ National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
• ⁵ Department of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany.
• ⁶ Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany.
• ⁷ Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.
• ⁸ Department of Internal Medicine III, University Hospital Mainz, Mainz, Germany.
• ⁹ Department for Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.
• ¹⁰ Medical Clinic, Charité University Medicine Berlin, Berlin, Germany.
• ¹¹ Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
• ¹² Department of Hematology, Oncology and Immunology, Phillips-University Marburg, Marburg, Germany.
• ¹³ Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
• ¹⁴ Department of Hematology, Oncology, Ruhr-University Bochum, Bochum, Germany.
• ¹⁵ Department of Internal Medicine II, University Hospital Frankfurt a.M., Frankfurt a.M., Germany.
• ¹⁶ Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
• ¹⁷ Hematology/Oncology Center, Koblenz, Germany.
• ¹⁸ Evang. Kliniken Essen-Mitte, Evang. Krankenhaus Essen-Werden, Essen, Germany.
• ¹⁹ Internal Medicine I, Hospital Mutterhaus der Borromäerinnen, Trier, Germany.
• ²⁰ Department of Hematology, Oncology and Gastroenterology, Kliniken Maria Hilf GmbH, Mönchengladbach, Germany.
• ²¹ Hematology/Oncology Center, Lebach, Germany.
• ²² Hematology, Oncology, Palliative Care, SLK Clinics Heilbronn, Heilbronn, Germany.
• ²³ Hematology and Oncology, Westpfalz-Klinikum, Kaiserslautern, Germany.
• ²⁴ Mannheimer Onkologie Praxis, Mannheim, Germany.
• ²⁵ Coordination Centre for Clinical Trials (KKS) Heidelberg, Heidelberg, Germany.
• ²⁶ Asklepios Tumorzentrum Hamburg, Asklepios Hospital Hamburg Altona and St. Georg, Hamburg, Germany.
• ²⁷ Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
• ²⁸ Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany. michael.hundemer@med.uni-heidelberg.de.